About this Research Topic
Delivery of pharmaceuticals, nanomaterials, imaging agents, and biomolecular manipulation tools is critical for many biotechnology and bioengineering fields, ranging from protein therapeutics to genome editing. Biological delivery is challenging, and is often the bottleneck in many cases, because biological systems (e.g., cells, brain, and tumors) present many natural transport barriers against objects deemed 'foreign'. In the past several decades numerous advanced delivery technologies have been reported to improve delivery performance in biological systems. Most recently, in the global fight against the COVID-19 pandemic, the use of nanoparticles-based delivery systems has been crucial to the success of some of the best vaccines.
Translation of advanced delivery technologies to the clinic and industry has proven to be extremely challenging. Success stories like the above-mentioned delivery systems for COVID-19 vaccines remain very limited. This Research Topic aims to provide a platform for bridging fundamental research in biological delivery with the clinic and industry. New advances, reviews and opinions that can facilitate dialogues and translation will be published in this Research Topic.
This Research Topic publishes high quality articles on the broad topic of biological delivery, with a focus on bridging fundamental research with the clinic and industry. The submitted manuscripts could be in the form of Original Research articles, Reviews, Perspectives and Opinions. Specific themes include but are not limited to:
· Understanding the complex transport behaviors of exogenous entities in biological systems;
· Toxicology and immunology of nanomedicine;
· Delivery of proteins and RNA therapeutics and genome-editing tools;
· Scalable production of delivery systems;
· Overcoming delivery barriers of tumors, brain and the eye;
· Clinical studies of biological delivery technologies;
· Precision nanomedicine;
· Historical accounts of translation of delivery technologies to the clinic/industry;
· Delivery for theranostics;
· Delivery for regenerative medicine;
· Opinions on hurdles of translation.
Gang Ruan is a co-founder and equity holder of Core Quantum Technologies, a company developing nanomaterials-based products for biomedical analysis. He holds patents transferred to the company.
Keywords: Protein therapeutics, Genome editing, Translation, Immune engineering, Nanomedicine
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.